2026-06-14T03:37:38Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/89882024-09-27T08:21:43Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Rossello, Xavier author Rodriguez-Sinovas, Antonio author Vilahur, Gemma author Crisóstomo, Verónica author Jorge, Inmaculada author Zaragoza, Carlos author Zamorano, José L author Bermejo, Javier author Ordoñez, Antonio author Boscá, Lisardo author Vazquez, Jesus author Badimón, Lina author Sánchez-Margallo, Francisco Miguel author Fernández-Avilés, Francisco author Garcia-Dorado, David author Ibáñez, Borja author 2019-12-30 Despite many cardioprotective interventions have shown to protect the heart against ischemia/reperfusion injury in the experimental setting, only few of them have succeeded in translating their findings into positive proof-of-concept clinical trials. Controversial and inconsistent experimental and clinical evidence supports the urgency of a disruptive paradigm shift for testing cardioprotective therapies. There is a need to evaluate experimental reproducibility before stepping into the clinical arena. The CIBERCV (acronym for Spanish network-center for cardiovascular biomedical research) has set up the "Cardioprotection Large Animal Platform" (CIBER-CLAP) to perform experimental studies testing the efficacy and reproducibility of promising cardioprotective interventions based on a pre-specified design and protocols, randomization, blinding assessment and other robust methodological features. Our first randomized, control-group, open-label blinded endpoint experimental trial assessing local ischemic preconditioning (IPC) in a pig model of acute myocardial infarction (n = 87) will be carried out in three separate sets of experiments performed in parallel by three laboratories. Each set aims to assess: (A) CMR-based outcomes; (B) histopathological-based outcomes; and (C) protein-based outcomes. Three core labs will assess outcomes in a blinded fashion (CMR imaging, histopathology and proteomics) and 2 methodological core labs will conduct the randomization and statistical analysis. Sci Rep. 2019; 9(1):20290 10.1038/s41598-019-56613-6 2045-2322 2045-2322 Scientific reports 31889088 http://hdl.handle.net/20.500.12105/8988 CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions